Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse 01:31:48 03/05/2024 am IST After market 05:30:00 am
27.7 USD +1.91% Intraday chart for Pfizer, Inc. 27.68 -0.07%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Wall Street: optimism ahead of NFP, rates ease CF
PFIZER INC : Buy rating from DZ Bank ZD
Morgan Stanley Adjusts Price Target on Pfizer to $29 From $28 MT
Leerink Adjusts Price Target on Pfizer to $29 From $27 MT
BMO Capital Adjusts Pfizer's Price Target to $36 From $33, Keeps Outperform Rating MT
Moderna quarterly sales beat expectations but plummet from previous year RE
Morgan Stanley Lifts Price Target on Pfizer to $29 From $28, Keeps Equalweight Rating MT
Health Care Climbs as Pfizer, GSK Rise -- Health Care Roundup DJ
US Equity Markets Close Mixed Wednesday After Fed Holds Rates Steady MT
Sector Update: Health Care Stocks Rise Late Afternoon MT
PFIZER INC : Jefferies gives a Buy rating ZD
Trending : Pfizer 1Q Earnings Top Estimates; Raises FY24 View DJ
Sector Update: Health Care Stocks Advance Wednesday Afternoon MT
News Highlights : Top Company News of the Day - Wednesday at 1 PM ET DJ
Top Midday Stories: CVS Reports Q1 Earnings Miss, Lowers Outlook; ADP Q1 Earnings Top Estimates; J&J Proposes $6.5 Billion Settlement for Talc Lawsuits MT
News Highlights : Top Company News of the Day - Wednesday at 11 AM ET DJ
Pfizer lifts profit view on cost cuts RE
Pfizer Plans to Launch Online Platform for COVID-19, Migraine Drugs MT
Transcript : Pfizer Inc., Q1 2024 Earnings Call, May 01, 2024
News Highlights : Top Company News of the Day - Wednesday at 9 AM ET DJ
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday MT
PFIZER INC : UBS remains Neutral ZD
Pfizer Lifts Full-Year 2024 Earnings Outlook Following First-Quarter Beat MT
PFIZER INC : JP Morgan remains Neutral ZD
Pfizer Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Chart Pfizer, Inc.
More charts
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
27.7 USD
Average target price
31.89 USD
Spread / Average Target
+15.14%
Consensus
  1. Stock Market
  2. Equities
  3. PFE Stock
  4. News Pfizer, Inc.
  5. Pfizer to Study Repeat Paxlovid Regimen at FDA Order, Details to be Finalized This Month